CeraVx B.V. is a biotechnology company developing a proprietary microneedle drug-delivery platform designed to improve the administration of vaccines and therapeutics. The company’s technology, CeraMap™, uses ceramic microneedle array patches to deliver drugs intradermally in a minimally invasive and potentially painless way.

By targeting the immune-cell-rich layers of the skin, the platform can enhance immune responses while potentially reducing the required dose of active compounds. The technology is designed to be compatible with a wide range of vaccines, biologics, and small-molecule therapeutics.

CeraVx collaborates with biopharmaceutical partners to advance microneedle-based delivery solutions for next-generation vaccines and therapeutics.

Are you also interested to pitch your company at the next edition of Health~Holland Global Investor Forum and Innovation for Health on 10-11 March 2027 in Utrecht, the Netherlands? Then sign up for the event newsletter to stay informed.